---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-24-000078"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:04:38.492440+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M

## Summary
- Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.
- Net loss $35.4M ($0.32/sh) vs $80.1M ($1.31/sh) in Q1 2023; cash $404.5M at March 31.
- PDUFA date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis (ages 6+).
- Completed $172.5M public offering in February; licensing deal with Sato Pharma for Japan.
- Appointed David Topper CFO effective April 10, 2024; sNDA for scalp/body psoriasis expected Q3 2024.

## SEC filing metadata
- accession: 0001787306-24-000078
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/0001787306-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/arqt-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-24-000078
- JSON: https://secwatch.observer/filing/0001787306-24-000078.json
- Plain text: https://secwatch.observer/filing/0001787306-24-000078.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.6 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $21.6 million
  - Result: reported results
  source text: 3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com First Quarter 2024 Summary Financial Results Product revenues for the quarter ended March 31, 2024 were $21.6 million compared to $2.8 million for the corresponding period in 2023. Revenues for the quarter were $15.0 million for ZORYVE (roflumilast) cream 0.3% and $6.5 million for ZORYVE
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/0001787306-24-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.